Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Pre-participation screening of young competitive athletes for prevention of sudden cardiac death 3. The Job Market for 2008-2009: Compensation 4. Renal Artery Stenosis 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
The Role of Nicotinamide Adenine Dinucleotide Phosphate Oxidase in the Pathogenesis of Hypertension
High Blood Pressure & Cardiovascular Prevention, 09/21/09
Loffredo L et al. – Nicotinamide adenine dinucleotide phosphate (NADPH) activation is considered as the major reactive oxygen species source and could be implicated in the pathogenesis of hypertension. A large body of evidences coming from animal studies have generally supported the hypothesis that high blood pressure is associated with increased oxidative stress and with NADPH activation; conversely, human studies provided divergent results. This review analyses the data reported so far to determine the role of NADPH oxidase in the pathogenesis of hypertension.
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09
Effectiveness of Two-Year Clopidogrel + Aspirin in Abolishing the Risk of Very Late Thrombosis After Drug-Eluting Stent Implantation (from the TYCOON [Two-Year ClOpidOgrel Need] Study)
The American Journal of Cardiology, 11/05/09
Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for Dyslipidemia
Annals of Internal Medicine, 11/03/09
Today in Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy
Current Medical Research and Opinion, 11/23/09
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial
The Lancet, 10/27/09
Current options for the treatment of resistant hypertension
Expert Review of Cardiovascular Therapy , 11/13/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


